I
Inhibikase Therapeutics, Inc.
IKT · NASDAQ · Healthcare · 318M
Closing price
$1.97
+3.14% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
1.1×
Enterprise value / EBITDAEV/EBITDA
-1.0×
Free cash flow yieldFCF yield
-14.3%
Return on equityROE
-27.9%
Operating margin
—
Net debt / EBITDAbalance-sheet strength
2.6×
Interest coverage
—
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.